THE COVID 19 SERVICES CATALYZE TRANSLATIONAL RESEARCH FINDINGS INTO PUBLIC HEALTH CHANGES TO ADDRESS THE NOVEL CORONAVIRUS PANDEMIC THROUGH IMPLEMENTATION OF STANDARDIZED SEROLOGY TESTING FOR ITS INTE

应为治疗发展处提供下列支助： ·继续在Leidos Biomedical Research，Inc.与高级生物医学计算科学合作开展“罕见病综合数据资源”； ·药品和药品批次的检验验证和非GMP和GMP生产； ·稳定性研究，以支持使用GMP和/或非GMP产品的项目； ·生物分布/成像和药代动力学研究； ·开发生物分析方法的咨询服务； ·监管服务，以支持临床前和/或临床阶段项目； ·电子显微镜研究； ·基因表达和蛋白质组数据分析以及基于细胞的筛选研究； ·犬类比较肿瘤学的蛋白质组学分析、基于细胞的疗效研究和临床试验； ·实验室动物支持。

The following support shall be provided for Therapeutic Development Branch: • Continuation of the "Integrated Data Resource for Rare Diseases" working with Advanced Biomedical Computational Science at Leidos Biomedical Research, Inc.; • Assay validation and non-GMP and GMP manufacturing of batches of drug substance and drug product; • Stability studies to support projects with GMP and / or non-GMP products; • Biodistribution / imaging and pharmacokinetic studies; • Consulting services for development of bioanalytical methods; • Regulatory services to support preclinical and / or clinical-stage projects; • Electron microscopy studies; • Gene expression and proteomic data analyses and cell-based screening studies; • Proteomic profiling, cell-based efficacy studies, and clinical trials for canine comparative oncology; • Laboratory animal support.